Overview
BBNX market data
Price History
BBNX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.81 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.26 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -61.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.80 – $32.71 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $737.8M · P/B 4.66 · P/S 6.20.
Company News
Beta Bionics Affirms FY2026 Sales Guidance of $131.000M-$136.000M vs $133.305M EstBenzinga · Jul 29, 2026, 8:02 PM
Beta Bionics Q2 EPS $(0.53) Beats $(0.56) Estimate, Sales $32.013M Beat $31.443M EstimateBenzinga · Jul 29, 2026, 8:02 PM
Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19Benzinga · Jul 15, 2026, 4:46 PM
Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $22Benzinga · Jul 13, 2026, 4:09 PM
Robbins LLP Reminds BBNX Stockholders of its Investigation into Beta Bionics, Inc.; Contact the Firm for InformationGlobenewswire Inc · Jun 5, 2026, 11:15 PM
Beta Bionics Announces Near Real-Time Real-World Data On iLet Bionic Pancreas Is Now Publicly Available At betabionics.com/hcp/real-world-dataBenzinga · Jun 2, 2026, 1:09 PM
Goldman Sachs Maintains Buy on Beta Bionics, Lowers Price Target to $17Benzinga · May 27, 2026, 5:35 PM
Beta Bionics Intends To Fully Commercialize Mint By Q2 2027Benzinga · May 21, 2026, 8:10 PM
8-K filing — Beta Bionics, Inc. (BBNX)SEC EDGAR · May 21, 2026, 8:06 PM
B of A Securities Maintains Neutral on Beta Bionics, Lowers Price Target to $11Benzinga · May 18, 2026, 5:35 PM